← Leaderboards
Thomas R Ziegler
Emory University
$10,822,263
Attributed
$11,448,684
Total exposure
21
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–23$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$11,448,684 · 21
By mechanism
U01$3,997,657 · 1
K24$1,726,786 · 2
R21$1,662,476 · 4
R01$1,521,100 · 1
M01$1,270,012 · 9
P30$895,002 · 2
Top collaborators
- Vaia Lida Chatzi2 shared
- Dean P. Jones2 shared
- Gregory S Martin2 shared
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchMetabolicBaseGlutamineShort Bowel SyndromePlasmaOperative Surgical ProceduresNutritionResearch PersonnelHuman SubjectResourcesHuman Therapy EvaluationCritical IllnessMorbidity - Disease RateOxidation-ReductionGlutathioneFundingTranslational ResearchFunctional DisorderHospitalsCell PhysiologyBloodDouble-Blind MethodGastrointestinal Absorption /Transport
Grant awards (59)
Core 1, DEG$343,428
P30 · FY2023 · DK · contact PI
Core 1: Diabetes, GI & Nutrition, Ziegler$178,045
P30 · FY2022 · DK · contact PI
Core 1: Diabetes, GI & Nutrition, Ziegler$178,020
P30 · FY2021 · DK · contact PI
Core 1: Diabetes, GI & Nutrition, Ziegler$195,509
P30 · FY2020 · DK · contact PI
The adipose exposome effects on the plasma metabolome, body composition and metabolic outcomes after bariatric surgery$237,345
R21 · FY2019 · ES · contact PI
The adipose exposome effects on the plasma metabolome, body composition and metabolic outcomes after bariatric surgery$218,135
R21 · FY2018 · ES · contact PI
High-Resolution Plasma Metabolomic Profiling to Identify Biomarkers for Tuberculosis Disease and Response to Therapy$201,669
R21 · FY2018 · AI · contact PI
High-Resolution Plasma Metabolomic Profiling to Identify Biomarkers for Tuberculosis Disease and Response to Therapy$240,669
R21 · FY2017 · AI · contact PI
Patient Oriented Research In Clinical Nutrition$177,529
K24 · FY2016 · DK · contact PI
Patient Oriented Research In Clinical Nutrition$177,529
K24 · FY2015 · DK · contact PI
Patient Oriented Research In Clinical Nutrition$177,529
K24 · FY2014 · DK · contact PI
Patient Oriented Research In Clinical Nutrition$177,529
K24 · FY2013 · DK · contact PI
Comparative effectiveness of energy dose in critical illness$193,750
R21 · FY2012 · DK · contact PI
HIGH-DOSE VITAMIN D AND ANTIMICROBIAL PEPTIDE EXPRESSION IN LUNG FAILURE$193,650
R21 · FY2012 · HL
Patient Oriented Research In Clinical Nutrition$177,529
K24 · FY2012 · DK · contact PI
Efficacy and Mechanisms of GLN Dipeptide in the SICU$90,938
U01 · FY2012 · DK · contact PI
Comparative effectiveness of energy dose in critical illness$215,883
R21 · FY2011 · DK · contact PI
Patient Oriented Research in Clinical Nutrition$174,655
K24 · FY2011 · RR · contact PI
HIGH-DOSE VITAMIN D AND ANTIMICROBIAL PEPTIDE EXPRESSION IN LUNG FAILURE$161,375
R21 · FY2011 · HL
Patient Oriented Research in Clinical Nutrition$171,140
K24 · FY2010 · RR · contact PI
Efficacy and Mechanisms of GLN Dipeptide in the SICU$620,824
U01 · FY2009 · DK · contact PI
Efficacy and Mechanisms of GLN Dipeptide in the SICU$599,746
U01 · FY2009 · DK · contact PI
Patient Oriented Research in Clinical Nutrition$167,729
K24 · FY2009 · RR · contact PI
Efficacy and Mechanisms of GLN Dipeptide in the SICU$150,000
U01 · FY2009 · DK · contact PI
Efficacy and Mechanisms of GLN Dipeptide in the SICU$609,749
U01 · FY2008 · DK · contact PI
Patient Oriented Research in Clinical Nutrition$164,417
K24 · FY2008 · RR · contact PI
Efficacy and Mechanisms of GLN Dipeptide in the SICU$648,766
U01 · FY2007 · DK · contact PI
Patient Oriented Research in Clinical Nutrition$161,200
K24 · FY2007 · RR · contact PI
Efficacy and Mechanisms of GLN Dipeptide in the SICU$55,080
U01 · FY2007 · DK · contact PI
MULTICENTER STUDY OF L-GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA & SICKLE B-THAL$14,908
M01 · FY2007 · RR · contact PI
MECHANISMS OF ADAPTATION IN HUMAN SHORT BOWEL SYNDROME$3,089
M01 · FY2007 · RR · contact PI
A STUDY OF THE EFFICACY AND SAFETY OF TEDUGLUTIDE IN SUBJECTS WITH PARENTAL N$2,953
M01 · FY2007 · RR · contact PI
EFFICACY OF GLUTATHIONE OR GLUTATHIONE PLUS ORATTE LOZENGES TO PREVENT OR ATT$805
M01 · FY2007 · RR · contact PI
EFFICACY AND MECHANISMS OF GLN DPEPTIDE IN THE SICU$134
M01 · FY2007 · RR · contact PI
Efficacy and Mechanisms of GLN Dipeptide in the SICU$543,455
U01 · FY2006 · DK · contact PI
Efficacy and Mechanisms of GLN Dipeptide in the SICU$55,080
U01 · FY2006 · DK · contact PI
GLUTATHIONE LOZENGES IN THE PREVENTION MUCOSITIS IN RADIATION THERAPY$4,462
M01 · FY2006 · RR · contact PI
Efficacy and Mechanisms of GLN Dipeptide in the SICU$624,019
U01 · FY2005 · DK
Mechanisms of Adaptation in Human Short Bowel Syndrome$145,401
R03 · FY2005 · DK
ADAPTATION IN HUMAN SHORT BOWEL SYNDROME$87,885
M01 · FY2005 · RR
GLUTATHIONE LOZENGES IN THE PREVENTION MUCOSITIS IN RADIATION THERAPY$263
M01 · FY2005 · RR
DIET/GROWTH FACTOR MECHANISMS OF GUT ADAPTATION$305,687
R01 · FY2004 · DK
Adaptation in Human Short Bowel Syndrome$276,306
M01 · FY2004 · RR
Mechanisms of Adaptation in Human Short Bowel Syndrome$153,000
R03 · FY2004 · DK
DIET/GROWTH FACTOR MECHANISMS OF GUT ADAPTATION$296,909
R01 · FY2003 · DK
ADAPTATION IN HUMAN SHORT BOWEL SYNDROME$293,069
M01 · FY2002 · RR
ADAPTATION IN HUMAN SHORT BOWEL SYNDROME$293,069
M01 · FY2002 · RR
DIET/GROWTH FACTOR MECHANISMS OF GUT ADAPTATION$288,382
R01 · FY2002 · DK
DIET/GROWTH FACTOR MECHANISMS OF GUT ADAPTATION$30,798
R01 · FY2002 · DK
METABOLIC AND CLINICAL EFFICACY IN TUBE FED PATIENTS$0
M01 · FY2002 · RR
BLOOD NEOPLASM--TBI &HI DOSE CHEMOTHERAPY W /TRANSPLANT$0
M01 · FY2002 · RR
BLOOD NEOPLASM--TBI &HI DOSE CHEMOTHERAPY W /TRANSPLANT$0
M01 · FY2002 · RR
METABOLIC AND CLINICAL EFFICACY IN TUBE FED PATIENTS$0
M01 · FY2002 · RR
DIET/GROWTH FACTOR MECHANISMS OF GUT ADAPTATION$300,340
R01 · FY2001 · DK
ADAPTATION IN HUMAN SHORT BOWEL SYNDROME$293,069
M01 · FY2001 · RR
BLOOD NEOPLASM--TBI &HI DOSE CHEMOTHERAPY W /TRANSPLANT$0
M01 · FY2001 · RR
METABOLIC AND CLINICAL EFFICACY IN TUBE FED PATIENTS$0
M01 · FY2001 · RR
DIET/GROWTH FACTOR MECHANISMS OF GUT ADAPTATION$298,984
R01 · FY2000 · DK
EFFICACY OF GLUTAMINE DIPEPTIDE IN CATABOLIC PATIENTS$77,250
R03 · FY2000 · DK